They're not looking at the bigger picture; they're just looking at dollar signs. I don't want to be labeled as a dollar sign.

We came across a bullish thesis on REGENXBIO Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls ...

For more than 10 years, Napa in Newport has been the signature event to raise funds and awareness for CureDuchenne, a Newport ...

As biotechs faced investors at the J.P. Morgan Healthcare Conference this week, they emphasized agreement with the FDA on ...

Solid Biosciences Inc. company and executive profile by Barron's. View the latest SLDB company infomation and executive bios.

Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for ...

Sarepta Therapeutics saw its stock skid 11% after the company announced preliminary unaudited 2025 sales results that missed analyst forecasts for its marketed Elevidys® (delandistrogene ...

Together with his brothers, twin Edward, younger sibling William, 24, big brother Oliver, 30, and their cousin Rupert Lowther ...

Atossa Therapeutics said the FDA gave an orphan drug designation to its drug Z-Endoxifen to treat Duchenne muscular dystrophy. Shares gained 16% to 71 cents in after-hours trading Friday.

Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease Designation ...

Biolexis Therapeutics Inc. has identified AMP-activated protein kinase (AMPK) activators reported to be useful for the treatment of diabetes, ischemia-reperfusion injury, dyslipidemia, obesity, ...